



Crescendo to participate in upcoming investor conferences

Cambridge, UK, 27 April 2021 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that senior members of the executive team will be participating at the following two investor conferences:

- **SVB Leerink Biopharma Private Company Connect Event, 6-7 May 2021**
Theodora Harold (CEO), Phil Bland-Ward (CDO) and Mike Booth (CFO) will be attending to meet investors to discuss the Company's business strategy, technology, discovery and development programmes.
- **BioEquity Europe 2021, 17-19 May**
Theodora Harold (CEO) and Mike Booth (CFO) will be attending, and Theodora will also be a panelist in the faculty session, *BioCentury Scene Setter: Reading the Next Act*, on Monday 17 May.

Both events will be virtual. If you are interested in meeting the team at these events, please contact the Company via email at investors@crescendobiologics.com.

Please refer to individual conference websites for further information and updated schedules.

-Ends-

For more information, please contact:

Crescendo Biologics

Theodora Harold, CEO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Siobhan Sanford,
Nathan Billis
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody® for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anticancer effect whilst avoiding systemic toxicity.



The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com and follow [@HUMABODY](https://twitter.com/HUMABODY).